ESC 365 - Drug therapy in adult congenital heart disease: the burden of polypharmacy

ESC Premium Access

Drug therapy in adult congenital heart disease: the burden of polypharmacy

Session: Drug therapy in congenital heart disease - What are the options and the needs?

Topic: Epidemiology, Prognosis, Outcome

Speaker: Ms O. Woudstra (Amsterdam, NL)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Ms Odilia Woudstra

Amsterdam University Medical Centre, Amsterdam (Netherlands (The))

0 follower

4 more presentations in this session

Thromboembolic prevention in adolescents and adults with Fontan circulation: Is ASS a therapeutical option in long-standing Fontan circulation?

Speaker: Assistant Professor M. Westhoff-Bleck (Hannover, DE)

Thromboembolism and bleeding in adults with congenital heart disease using non-vitamin K antagonist oral anticoagulants for thromboembolic prevention: a prospective worldwide observational study

Speaker: Miss H. Yang (Singapore, SG)

Combination of fenestrated atrial septal occluder with targeted medical therapy in patients with secundum atrial septal defect and severe pulmonary arterial hypertension

Speaker: Doctor C. Yan (Beijing, CN)

Selective Heart Rate inhibition improves inadequate exercise response in Fontan Circulation

Speaker: Mr B. Ruijsink (London, GB)

Access the full session

Drug therapy in congenital heart disease - What are the options and the needs?

Speakers: Ms O. Woudstra, Assistant Professor M. Westhoff-Bleck, Miss H. Yang, Doctor C. Yan, Mr B. Ruijsink

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources